Biolinq Shine: First FDA-Cleared Needle-Free Glucose Sensor with Color-Coded LED Display

The first wearable glucose sensor to receive FDA de novo clearance without using a needle or filament, employing a microsensor array that sits in the uppermost skin layers to provide color-coded LED glucose trend feedback from a forearm patch worn for 5 to 7 days.

Presented By Our Partners

Continuous glucose monitoring has transformed diabetes management over the past decade, but every commercially available CGM requires inserting a filament or needle through the skin to reach interstitial fluid in the subcutaneous tissue. This insertion creates a wound channel that must heal around the sensor, limits wear duration, risks infection at the insertion site, and presents a psychological barrier for needle-averse patients. A 2023 systematic review published in Diabetes Technology and Therapeutics by Klonoff et al. found that while CGM adoption has expanded dramatically, needle-related anxiety remains a significant barrier to uptake, particularly among newly diagnosed patients and pediatric populations (DOI: 10.1089/dia.2023.0110).

A 2022 review published in Nature Reviews Endocrinology by Teymourian et al. surveyed the landscape of non-invasive and minimally invasive glucose monitoring technologies, concluding that while numerous approaches have been proposed (optical, electrochemical, microwave, and others), none had achieved the accuracy and regulatory approval needed for clinical use. The fundamental challenge is that glucose concentration in accessible body fluids (sweat, tears, saliva) is orders of magnitude lower than in blood, making accurate measurement extremely difficult without accessing interstitial or blood compartments directly (DOI: 10.1038/s41574-021-00620-1). The Biolinq Shine represents a potential breakthrough in this landscape: the first glucose sensor to receive FDA clearance without using a traditional needle or filament insertion system.

What Is the Biolinq Shine?

The Biolinq Shine is a wearable glucose monitoring patch developed by Biolinq that received FDA de novo classification on September 23, 2025, making it the first glucose sensor to achieve regulatory clearance without requiring needle or filament insertion. The device is worn as a small patch on the forearm and uses a proprietary microsensor array that accesses glucose in the uppermost layers of the skin, sitting up to 20 times shallower than conventional CGM sensors.

Rather than penetrating to the subcutaneous tissue where traditional CGMs measure interstitial fluid glucose, Biolinq’s microsensor array targets the intradermal space, the region just beneath the outermost skin layer. This ultra-shallow sensing approach eliminates the need for the insertion needle or applicator mechanism used by Dexcom, Abbott, and Medtronic CGMs, and creates a fundamentally different patient experience: no insertion pain, no wound channel, and no insertion anxiety.

The Shine displays glucose information through a built-in color-coded LED system directly on the patch itself. Rather than requiring users to check a phone app or receiver for every reading, the patch provides immediate visual feedback through color changes: blue indicates glucose levels within a healthy range, while yellow signals that glucose is trending outside the target range. This at-a-glance design philosophy simplifies glucose awareness for users who find traditional CGM data streams (continuous numerical readings, trend arrows, graphs) overwhelming or overcomplicating.

Each Shine patch is designed for 5 to 7 days of wear. The device also tracks physical activity and sleep data, viewable through a connected mobile app, positioning it as a multi-metric health patch rather than a glucose-only sensor.

The FDA’s de novo clearance classifies the Shine as providing qualitative glucose range and trend information rather than the quantitative continuous readings used for insulin dose calculations. This means the Shine is cleared for glucose awareness and trend monitoring, not for replacing traditional CGMs in insulin-dosing decisions.

The Science Behind Intradermal Glucose Sensing

Traditional CGM technology measures glucose in interstitial fluid (ISF) within the subcutaneous tissue, typically 4 to 8 millimeters below the skin surface. A filament sensor is inserted to this depth and remains in place for the wear period (7 to 15 days depending on the device), continuously measuring glucose through enzymatic electrochemical reactions. The glucose concentration in ISF correlates with blood glucose but exhibits a physiological lag of approximately 5 to 15 minutes due to the time required for glucose to diffuse from blood capillaries into the surrounding tissue fluid.

Biolinq’s approach targets the dermis, the layer of skin between the epidermis (outermost layer) and the subcutaneous tissue. The dermis contains a rich capillary network that supplies the skin with blood, and glucose is present in the dermal interstitial fluid at concentrations that correlate with blood glucose. By using a microsensor array with extremely short sensing elements that access only the superficial dermal layer, Biolinq avoids the deeper insertion required by traditional CGMs.

The microsensor array technology consists of multiple tiny sensing elements arranged on the patch surface. Each element is designed to access the intradermal space without the pain or tissue disruption associated with traditional needle insertion. The multi-sensor approach provides redundancy: if individual sensing elements encounter variable contact with the dermis, the array’s collective signal can be algorithmically processed to produce a more reliable glucose estimate than any single sensor point.

The trade-off of intradermal versus subcutaneous sensing involves signal strength and accuracy. Glucose concentrations in the superficial dermis may be lower or more variable than in the deeper subcutaneous ISF, which is why the FDA clearance specifies qualitative trend monitoring rather than quantitative glucose values suitable for insulin dosing. Future sensor generations may achieve the accuracy needed for quantitative measurement as the technology matures.

What the Biolinq Shine Does Well

The elimination of needle insertion is a transformative user experience improvement. For the millions of people with diabetes who experience needle anxiety, insertion site pain, or skin reactions at traditional CGM sites, the Shine offers an alternative that removes the most aversive aspect of CGM use. This could expand CGM adoption to patient populations that have resisted or discontinued traditional CGMs specifically because of the insertion requirement.

The color-coded LED display on the patch itself is a remarkably simple interface design. Traditional CGMs generate continuous data streams that require smartphone apps, receivers, or smartwatch displays to interpret. For many patients, particularly older adults and those with limited technology comfort, this data complexity is a barrier. The Shine’s approach of communicating glucose status through color (blue for in-range, yellow for out-of-range) makes glucose awareness accessible without any screen interaction.

The 5 to 7 day wear period with no insertion procedure makes the application experience comparable to applying a bandage or adhesive patch. This simplicity could enable broader adoption in primary care settings where clinicians may be less experienced with CGM insertion procedures, and in populations (pediatric, elderly, cognitively impaired) where the insertion process presents practical challenges.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The integration of activity and sleep tracking transforms the Shine from a glucose-only sensor into a multi-metric health patch that can help users correlate glucose patterns with lifestyle factors. Understanding how exercise, sleep quality, and daily activity patterns influence glucose trends is actionable health intelligence that supports behavior change.

Pricing, Access, and Practical Realities

Following its FDA de novo clearance in September 2025, Biolinq raised a $100 million Series C funding round to scale production. The Shine is expected to officially reach the market in early 2026, initially targeting individuals with Type 2 diabetes.

Biolinq has not announced consumer pricing as of this writing. For context, traditional CGM pricing ranges from approximately $75 to $350 per month depending on insurance coverage and the specific system. Dexcom G7 sensors cost approximately $75 to $100 each (lasting 10 to 15.5 days) without insurance. Abbott FreeStyle Libre 3 sensors are priced at approximately $75 each (lasting 14 days). The Biolinq Shine’s 5 to 7 day wear period means higher sensor consumption per month than these competitors, which could affect total cost of ownership.

Insurance coverage and reimbursement pathways have not been established. As a de novo classified device with a qualitative rather than quantitative glucose indication, the Shine occupies a novel regulatory category that payers have not previously evaluated. The coverage landscape will significantly influence accessibility and adoption.

Users should understand the Shine’s clearance scope: it provides glucose trend awareness (directional information about whether glucose is in range or trending out of range) rather than the precise glucose values used for insulin dosing decisions. Patients on insulin therapy who rely on CGM data for dosing calculations will still need a traditional CGM for that purpose. The Shine serves a complementary role: broader glucose awareness for Type 2 diabetes management, lifestyle optimization, and patients who cannot or will not use needle-based systems.

Who It Is Best For

The Biolinq Shine is best suited for individuals with Type 2 diabetes who are not on intensive insulin therapy and want glucose trend awareness without the complexity and invasiveness of traditional CGMs. The approximately 28 million Americans with Type 2 diabetes who manage their condition through diet, exercise, and oral medications represent the primary target population. For these patients, knowing whether glucose is trending in or out of range provides actionable feedback on dietary and activity choices without requiring the precise numerical data needed for insulin dose calculations.

Needle-averse patients who have avoided or discontinued traditional CGMs specifically because of insertion anxiety represent a critical underserved population. The Shine’s non-invasive application could bring glucose monitoring to patients who would otherwise have no continuous glucose visibility.

The Shine is also well-suited for wellness-oriented individuals without diabetes who want glucose awareness as part of a broader metabolic health optimization strategy. The growing consumer interest in glucose monitoring for weight management, energy optimization, and dietary personalization has been constrained by the invasiveness and cost of traditional CGMs. A non-invasive patch with simple visual feedback lowers the barrier substantially.

The device is not suited for patients who need quantitative CGM data for insulin dosing decisions. Individuals with Type 1 diabetes or insulin-dependent Type 2 diabetes should continue using FDA-cleared quantitative CGMs (Dexcom, Abbott, Medtronic) for treatment management.

How It Compares

Against the Dexcom G7 ($75 to $100/sensor, 10 to 15.5 day wear), the Shine offers a fundamentally different value proposition: non-invasive application versus needle insertion, qualitative trend information versus quantitative glucose values, and LED patch display versus smartphone app dependency. Dexcom G7 is the superior choice for insulin-dosing decisions; the Shine is the superior choice for needle-averse patients seeking glucose awareness.

Against the Abbott FreeStyle Libre 3 ($75/sensor, 14-day wear), similar distinctions apply. The Libre 3 offers quantitative readings, longer wear time, and established insurance coverage. The Shine offers non-invasive application and simpler visual feedback at the trade-off of less precise glucose data.

Against emerging non-invasive glucose monitoring competitors (various companies developing optical, microwave, and sweat-based approaches), the Shine holds the significant advantage of being the only non-invasive glucose device with FDA clearance. Most competing non-invasive approaches remain in research or pre-regulatory stages.

Against consumer wellness CGMs like Levels Health and Nutrisense (which use traditional needle-based Dexcom or Abbott sensors with software overlays), the Shine offers a non-invasive alternative that may appeal to wellness consumers deterred by the invasiveness of traditional CGM hardware.

Limitations and Open Questions

The qualitative nature of the FDA clearance is the most important limitation to understand. The Shine provides glucose range and trend information, not the precise glucose values (in mg/dL) that traditional CGMs display. This means users cannot see their exact glucose level, only whether it falls within or outside a target range. For patients accustomed to quantitative CGM data, this may feel like a significant information downgrade.

The 5 to 7 day wear period is shorter than all major traditional CGMs (Dexcom G7: 10 to 15.5 days; Libre 3: 14 days; Medtronic Guardian 4: 7 days). More frequent sensor changes increase cost, environmental waste, and user burden. Whether Biolinq can extend wear duration in future generations will affect long-term competitiveness.

Accuracy data from clinical trials has not been extensively published in peer-reviewed literature. The FDA clearance establishes regulatory acceptability for the qualitative indication, but independent clinical studies comparing Shine readings against blood glucose reference values would strengthen the evidence base.

The intradermal sensing approach is novel and may face challenges related to skin variability (thickness, hydration, temperature), adhesive performance across different skin types, and the effects of physical activity and sweating on sensor accuracy. Long-term data on these factors is limited given the product’s recent clearance.

Pricing and insurance coverage remain unknown. If the Shine is priced comparably to traditional CGMs per day of use but provides less precise data, the value proposition for insured patients may be challenging. The strongest use case may be for uninsured or underinsured patients seeking affordable glucose awareness, or wellness consumers not eligible for CGM coverage.

What This Means for Your Health

The Biolinq Shine represents a genuine inflection point in glucose monitoring technology. For the first time, glucose awareness is available without piercing the skin, removing the primary physical and psychological barrier that has limited CGM adoption to a fraction of the population that could benefit from it.

Metabolic health, centered on blood sugar stability and insulin sensitivity, is one of the foundational pillars of longevity science. Within Healthcare Discovery‘s Four Shadows framework, metabolic dysfunction underlies cardiovascular disease, contributes to neurodegenerative disease risk, and represents one of the most modifiable chronic disease pathways. The ability to monitor glucose trends non-invasively could democratize metabolic health awareness beyond the diabetes population to the broader population managing metabolic health proactively.

Within the Five Pillars framework, glucose monitoring connects directly to Nutrition (real-time feedback on how food choices affect blood sugar), Movement (understanding exercise’s glucose-lowering effects), and Sleep (tracking how sleep quality influences next-day glucose regulation). The Shine’s integrated activity and sleep tracking reinforces these connections by placing glucose data alongside the lifestyle metrics that drive it.

The practical impact depends on accessibility. If Biolinq can achieve competitive pricing and insurance coverage, the Shine could bring glucose awareness to millions of people with Type 2 diabetes who currently have no continuous visibility into their glucose patterns. For the broader wellness market, a non-invasive glucose patch at consumer-accessible pricing could catalyze the metabolic health monitoring revolution that needle-based CGMs have only partially delivered.

Frequently Asked Questions

What is the Biolinq Shine?
The Biolinq Shine is the first FDA-cleared needle-free glucose sensor, worn as a patch on the forearm. It uses a microsensor array that sits in the uppermost skin layers (up to 20 times shallower than traditional CGMs) to provide glucose trend information through a built-in color-coded LED display, with each patch lasting 5 to 7 days.

Is the Biolinq Shine FDA cleared?
Yes. The Biolinq Shine received FDA de novo classification on September 23, 2025, making it the first wearable glucose sensor cleared without requiring needle or filament insertion. The clearance is for qualitative glucose range and trend monitoring, not for quantitative glucose values used in insulin dosing.

How much does the Biolinq Shine cost?
Biolinq has not announced consumer pricing as of early 2026. The device is expected to reach the market in early 2026 following a $100 million Series C funding round to scale production. Insurance coverage and reimbursement pathways have not been established.

Can the Biolinq Shine replace my current CGM?
The Shine provides qualitative glucose trend information (in-range vs. out-of-range), not the precise glucose values used for insulin dosing. Patients on insulin therapy who rely on CGM data for dosing decisions should continue using their existing quantitative CGM. The Shine is best suited for Type 2 diabetes glucose awareness, lifestyle optimization, and patients who cannot use needle-based CGMs.

How is the Biolinq Shine different from traditional CGMs?
Traditional CGMs insert a filament 4 to 8mm under the skin to measure glucose in subcutaneous interstitial fluid. The Shine uses a microsensor array in the superficial dermis (top skin layers) without any needle. Traditional CGMs provide continuous numerical glucose values; the Shine provides color-coded trend information (blue = in range, yellow = out of range) with detailed data available through a companion app.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.